EscharEx Phase III interim data arrives as cash runs to Q2 2027, making the readout a survival event, not just a scientific one

MediWound is a clinical-stage company developing EscharEx, an enzymatic debridement agent for chronic venous leg ulcers, which is not yet approved.

MediWound's enzymatic debridement agent EscharEx, targeting chronic venous leg ulcers, enters a pre-specified Phase III interim assessment with runway that expires roughly the same quarter results are due. The thesis resolves on whether the interim shows sufficient efficacy signal to support continued enrollment, attract a partner, or unlock non-dilutive capital before cash runs out. The BARDA-backed NexoBrid revenue stream provides partial offset, but at current burn rates it does not close the financing gap if EscharEx disappoints.